drug · small molecule

TAFINLAR

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

targets

Serine/threonine-protein kinase B-raf

all catalysts(0)

nothing on the calendar yet

Trials studying TAFINLAR

—Special Drug Use-results Surveillance of Tafinlar/Mekinistrecruitingn=110
phase2Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancercompletedn=27

News(1)

Labcorp nabs FDA green light for BRAF melanoma diagnostic
The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.
fiercebiotech · 7d ago

brand

TAFINLAR

trade names

Finlee, Tafinlar

generic

DABRAFENIB MESYLATE

MOA

12.1 Mechanism of Action Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC 50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC 50 values of 3.2 and 5.0 nM, respectively, and other kinases, such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth [see Indications and Usage (1)] . Dabrafenib inhibits cell growth of various BRAF V600 mutation-positive tumors in vitro and in vivo. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation-positive tumor xenografts compared with either drug alone. In the setting of BRAF-mutant colorectal cancer, induction of EGFR-mediated MAPK pathway re-activation has been identified as a mechanism of intrinsic resistance to BRAF inhibitors [see Indications and Usage (1.8)].

indication

1 INDICATIONS AND USAGE TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) 1.1 BRAF V600E Mutation-Positive U

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 38m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

TAFINLAR

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

targets

Serine/threonine-protein kinase B-raf

all catalysts(0)

nothing on the calendar yet

Trials studying TAFINLAR

—Special Drug Use-results Surveillance of Tafinlar/Mekinistrecruitingn=110
phase2Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancercompletedn=27

News(1)

Labcorp nabs FDA green light for BRAF melanoma diagnostic
The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.
fiercebiotech · 7d ago

brand

TAFINLAR

trade names

Finlee, Tafinlar

generic

DABRAFENIB MESYLATE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 38m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

TAFINLAR

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TAFINLAR

News(1)

Report a data issue

comments(0)

TAFINLAR

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TAFINLAR

News(1)

Report a data issue

comments(0)